Early prostate cancer may have no symptoms, while benign enlargement or inflammation can also raise PSA, so neither urination patterns nor one result establishes a diagnosis. A urologist’s column cites European guidance to consider testing from age 50 at usual risk, 45 with close family history, and 40 with a pathogenic BRCA2 variant. The commonly used 4 ng/mL reference is not an absolute cutoff; age, medication and prior results inform repeat testing and further assessment. Share family history and screening records with a clinician and discuss unnecessary biopsies and overdiagnosis as well as early-detection benefits.
Back to Health
PSA screening timing depends on family history and genetic risk
An elevated result is not a cancer diagnosis; discuss early detection alongside overdiagnosis risk.